Ischaemic heart disease is the leading cause of death worldwide. Age is the strongest risk factor, yet older patients are consistently underrepresented in clinical trials. With an ageing population, knowledge of the evidence base for the treatment of older patients with acute coronary syndrome (ACS) is crucial. As people age, their responses to medications change, and they may become more susceptible to adverse effects of cardiovascular medications. Management of ACS in older people may be further complicated by the presence of comorbidities, polypharmacy and frailty. Treatment decisions need to be individualised, with consideration of patient preferences, functional and cognitive status and life expectancy. This review aims to summarise the current data for the management of older patients with ACS, with a focus on pharmacological treatment.
INTRODUCTION
Ischaemic heart disease (IHD) is a common condition and places significant burden on the healthcare system. It represents a spectrum of disease from stable angina through to acute coronary syndrome (ACS). The term 'ACS' encompasses unstable angina and myocardial infarction.
Age is the strongest risk factor for IHD and future cardiovascular risk, 1 yet older patients are consistently under-represented in, or even excluded from, cardiovascular medication and invasive treatment trials. This confounds the creation of evidence-based guidelines and adversely impacts clinical prognostication and selection of medical and interventional therapies. Cardiology societal guidelines may therefore have limited applicability to older patients, especially the frail elderly. The evidence for pharmacological management of ACS in the elderly is discussed in this article.
EPIDEMIOLOGY
IHD is the most common form of cardiovascular disease in Australia and the leading cause of death worldwide. 2 In 2007-08, there were 161 417 hospitalisations in Australia with a principal diagnosis of IHD, with 60% of patients aged 65 years and over. 2 Among Australians the incidence of ACS increases steadily with age, with the rate in people >85 years old (3005 per 100 000 population) over three times that for the 65-74 years age group (854 per 100 000 population) and six times the rate for the 55-64 age group (502 per 100 000 population). 1 
WHAT IS ELDERLY?
Australian healthcare data defines 'elderly' as >65 years old when recording the national burden of cardiovascular disease.
1 However, within cardiovascular trials, it is variably defined. Among major cardiology trials, 'elderly' has been defined as >75 years, >80 years and >90 years. [3] [4] [5] An important consideration when identifying a person as 'elderly' is level of function. Frailty is increasingly recognised as an important contributor to biological outcomes, and is frequently a more powerful predictor of clinical outcomes than chronological age. Frailty scores validated in cardiovascular assessment include the Edmonton Frail Scale, which is associated with increased comorbidity, longer length of stay in hospital, and mortality. 6 Multicentre prospective studies such as the FRASER trial 7 are in progress to assess the associations between frailty and mortality and readmission after ACS.
In this review, we use 'elderly' to generally mean >65 years old; however, where trials have reported explicit subgroups or age cut-offs, these are stated.
UNDER-REPRESENTATION OF ELDERLY PATIENTS IN CLINICAL TRIALS
In a 2001 review of 593 cardiovascular randomised controlled trials, patients >75 years of age accounted for only 10% of enrolled patients, and patients >85 years old accounted for only 2%. 8 Common reasons for non-enrolment of older patients include renal or hepatic dysfunction or explicit age exclusions; in the 1980s, 67% of cardiovascular trials used age >75 years old as an explicit exclusion criteria, falling to 40% in the 1990s. 8 Unfortunately, little has changed. A recent re-appraisal of the literature identified that 53% of studies published between 2006 and 2016 still carried an explicit age exclusion, with a median upper age limit of 80 years. 9 Given that the proportion of >85-year-olds is projected to increase by 151% in the next 15 years, 10 it is important to validate cardiovascular care in this group. Excluding older patients from cardiovascular trials undermines the external validity of trial findings.
CARDIOVASCULAR PHYSIOLOGY IN THE ELDERLY
As humans age, the pathophysiology and burden of atherosclerosis changes, with greater plaque burden, necrotic core volume and increased coronary calcification. 11 Ageing also causes progressive changes in cardiovascular physiology, altering the capacity to deal with IHD. Physiological ageing-related changes include endothelial dysfunction with a resultant decrease in nitric oxide release and vasodilatory potential, increased arterial wall stiffness, increased demand on cardiac function by way of increased afterload, reduced ventricular compliance, and impaired beta-adrenergic and parasympathetic function.
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The response to medications is also influenced by impaired function of other organ systems such as the liver and kidney (Figure 1) . Moreover, elderly patients are more likely to have multiple co-morbidities and polypharmacy. Consideration of drug-drug interactions is therefore essential in care of the older ACS patient. 13 
MEDICATIONS
Guidelines for ACS in the elderly are summarised in Table 1. 14-16 Despite a wealth of evidence for cardiovascular medication use in the general population, there are notable limitations in the data focusing specifically on the elderly population.
ANTIPLATELET AGENTS Aspirin
Aspirin remains the pre-eminent antiplatelet drug, typically instituted at the onset of IHD symptoms. Evidence for the benefit of aspirin is strong, as demonstrated by a meta-analysis of randomised trials which showed a 25% odds reduction for the secondary prevention of non-fatal myocardial ischaemia (MI). 17 The Cardiac Society of Australia and New Zealand, as well as the American College of Cardiology guidelines, recommend the use of aspirin at the onset of ACS in all patients, and for secondary prevention thereafter. 14, 15 Newer antiplatelet agents, including P2Y12 inhibitors (clopidogrel, ticagrelor and prasugrel) and glycoprotein IIb/IIIa inhibitors (abciximab), each have their own advantages, disadvantages and particular evidence base which influence their place in the medical therapy for IHD in the elderly.
Clopidogrel
The Percutaneous Coronary Intervention Clopidogrel in Unstable Angina to Prevent Recurrent Events (PCI-CURE) trial examined the use of clopidogrel in addition to aspirin in patients with non-ST segment elevation myocardial infarction (NSTEMI) with a mean age of 61.5 years who had undergone PCI. In the overall study population, clopidogrel plus aspirin was associated with a 31% relative risk reduction in cardiovascular death and MI before and after PCI compared to aspirin monotherapy. When the elderly population (defined in this study as >65 years) was examined they showed a smaller absolute and relative risk reduction in comparison to the younger cohort. 18 With regard to bleeding risk, elderly patients have been shown to have higher on-treatment platelet reactivity with clopidogrel; however, the exact increase in bleeding risk has not been quantified. 19 Randomised clinical trials currently in progress, such as the Elderly-ACS 2 study, aim to quantify the increase in bleeding risk and compare regimens of dose-reduced prasugrel to standard clopidogrel dosage. 19 In the setting of ST-segment elevation myocardial infarction (STEMI), the role of clopidogrel was assessed in the CLARITY-TIMI 28 trial. Among 3491 patients with a mean age of 57.7 years, the addition of clopidogrel to aspirin and thrombolysis resulted in a 36% relative reduction in the odds of death, recurrent MI or coronary occlusion. 20 As age over 75 years was an exclusion criterion for this trial, this evidence cannot be extrapolated to guide clopidogrel administration in elderly STEMI patients.
Prasugrel
The use of prasugrel was compared to clopidogrel in 13 608 patients with ACS undergoing PCI in the TRI-TON-TIMI 38 trial. 21 There were 1809 patients in this trial aged >75 years. The primary end-point was a composite of cardiovascular death, non-fatal MI and nonfatal stroke. Prasugrel was found to have a hazard ratio of 0.82 compared to clopidogrel. 21 However, patients aged >75 years did not derive the same benefits from prasugrel. A post-hoc exploratory analysis found that prasugrel in patients >75 years was associated with significant bleeding risks and no net clinical benefit (hazard ratio 0.99).
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The TRILOGY-ACS trial included an exploratory secondary analysis of the benefits of low-dose prasugrel (5 mg) in patients aged >75 years not undergoing PCI. There were no significant differences between prasugrel and clopidogrel with regards to bleeding risk or the primary composite endpoint of cardiovascular death, nonfatal MI or stroke. 22 
Ticagrelor
Ticagrelor is a novel antiplatelet agent increasingly used in the management of NSTEMI and STEMI. It acts as a nucleoside analogue to reversibly inhibit adenosine diphosphate (PGY12) receptors. The Platelet Inhibition and Patient Outcomes (PLATO) trial of 18 624 patients established the superiority of ticagrelor over clopidogrel, with significant reductions in all-cause mortality, cardiovascular mortality, MI and stroke. Only 2878 (15.5%) patients enrolled in the study were aged >75 years. 23 Rates of major bleeding did not differ between elderly patients treated with ticagrelor versus clopidogrel.
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Glycoprotein (GP) IIb/IIIa Inhibitors
GPIIb/IIIa inhibitors are a potent parenteral antiplatelet therapy, typically used in ACS patients undergoing percutaneous revascularisation. In general, their use is associated with improved short-term outcomes, including mortality and recurrent MI. 25 However, few trials have examined the use of GPIIb/IIIa agents in the elderly population. A retrospective analysis of the Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment (ISAR-REACT 2) study examined the efficacy of abciximab in patients aged ≤70 and >70 years. 26 After adjustment for baseline differences, a significant interaction was identified between age and abciximab with respect to reduction in rates of major adverse cardiovascular events (MACE). The greatest benefits of abciximab in the setting of NSTEMI were observed in younger patients. 26 Currently there are no recommendations in Australian guidelines for the use of the GPIIb/IIIa agents in the elderly. Their use in cardiac catheterisation laboratories is typically reserved for select scenarios of high thrombus burden, complex lesions or ongoing ischaemia.
ANTICOAGULANTS
Only one large study has examined the use of fractionated and unfractionated heparin in the elderly population. The ExTRACT-TIMI 25 trial compared the effect of enoxaparin versus heparin in STEMI patients undergoing fibrinolysis. Of 20 479 patients, 2532 (12.4%) were ≥75 years of age. 27 Patients aged 75 years and over received a modified enoxaparin dosing regimen (0.75 mg/kg by subcutaneous injection twice daily with no intravenous bolus). The relative risk reduction for the primary end-point of death or non-fatal MI in enoxaparin-treated patients compared to heparin-treated patients was 6%, although the 95% confidence interval overlapped zero. Based on this study, Australian and New Zealand guidelines recommend the use of enoxaparin in elderly patients with STEMI who have undergone fibrinolysis, at the reduced dose utilised in the ExTRACT-TIMI 25 trial.
14 The ATOLL trial randomised STEMI patients undergoing primary PCI to intravenous (IV) enoxaparin versus IV heparin, and reviewed a sub-group of 165 patients >75 years of age. Elderly patients who received IV enoxaparin (bolus dose of 0.5 mg/kg prior to PCI) had significantly lower rates of minor bleeding, but no reduction in major bleeding, compared to those who received IV heparin (bolus dose of 70-100 units/kg). 28 Enoxaparin's use in elderly patients has been compared to unfractionated heparin in the Superior Yield of the New strategy of Enoxaparin, Revascularization and GPIIb/IIIa inhibitors (SYNERGY) trial. In a subgroup of elderly (>75 years) NSTEMI patients, the efficacy of subcutaneous enoxaparin for reducing rates of death and myocardial infarction was similar to IV heparin, although enoxaparin was associated with increased risk of severe bleeding. 29 As a result, there is an emphasis in American College of Cardiology guidelines on dose reduction for enoxaparin based on patient age, clinical characteristics and renal function; the authors caution that 15% of major bleeding in elderly ACS patients can be attributed to overdosing of anticoagulants. 30 Direct thrombin inhibitors offer an alternative form of anticoagulation. Consensus recommendations suggest that bivalirudin may have a place in the management of elderly patients undergoing PCI considered to be at high bleeding risk, due to its favourable bleeding risk profile.
14 However, there is no clear evidence for its use in the elderly.
BETA-BLOCKERS
Ageing is associated with impairment of beta-adrenergic and parasympathetic function. It could therefore be anticipated that beta-blocker efficacy is altered. However, this is not borne out in practice. One retrospective cohort study of 5332 elderly ACS patients found that mortality was 43% lower in patients who received beta-blocker therapy within 90 days of their event compared to those who did not. These findings were consistent across all age groups (64-85 years). 31 Steinman et al. 32 examined betablocker use post-ACS in nursing home residents; although there was a mortality benefit from beta-blockade, patients with pre-existing substantial cognitive impairment experienced worsened functional decline, highlighting the need to consider risks and benefits in the frail elderly. Despite known mortality benefit, beta-blockers are often underprescribed in elderly patients, with as few as 21% of eligible patients receiving beta-blocker therapy.
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ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS
ACE inhibitors are generally well tolerated in the nonfrail elderly. Of all the classes of antihypertensive medications, they are least likely to increase risk of falls. 33 However, possible adverse effects of ACE inhibitors on renal function warrant consideration. The prevalence of chronic kidney disease increases rapidly with age after age 74, with rates among those aged 75 and over (42%) being twice as high as those aged 65-74 (21%) and eight times as high as for those aged 18-54 (6%). 34 In a subgroup analysis of the Fourth International Study of Infarct Survival (ISIS-4) trial of captopril versus placebo, mortality benefit for patients aged >70 years was not demonstrated. 35 However, other trials such as the Survival and Ventricular Enlargement Trial (SAVE Trial) found that in the setting of post-infarct left ventricular dysfunction, captopril significantly reduced mortality, with increased benefit seen in patients aged >65 years. 36 
STATINS
It has been postulated that the association between cholesterol levels and coronary risk diminishes with increasing age. 37 However, elderly patients have a greater risk of re-infarction and death after ACS compared to younger patients with equivalent cholesterol levels and risk factor profiles, and there is evidence that older patients benefit from statin therapy following ACS.
38
A retrospective analysis of 18 311 elderly ACS patients managed on either high-intensity or moderateintensity statin therapy demonstrated no difference in all cause-mortality and recurrent ACS between the two dose regimens. 39 This is consistent with findings from a sub-group analysis (patients aged >65 years) of the PROVE IT-TIMI 22 trial which showed no advantage of high-intensity atorvastatin over moderate-intensity pravastatin. 40 Consequently, cardiology society guidelines recommend the use of lower-intensity statin therapy in those with increased risk factors for side-effects to statins, 15, 16 including the elderly who are more likely to have impaired hepatic function and are at risk for interactions with other medications.
INVASIVE MANAGEMENT
Invasive management refers to coronary angiography, and may include percutaneous coronary intervention. Given the clear benefits, STEMI patients routinely undergo invasive management regardless of age, unless there are clear contraindications (i.e. prolonged downtime with cardiac arrest, severe frailty, advanced care plan indicating non-invasive management only). However, the role of an invasive approach in elderly NSTEMI patients has been questioned in recent years. One of the first studies which compared an invasive approach to conservative management in an elderly population was the Italian Elderly ACS study. In this study 313 patients aged >75 years with NSTEMI were randomised to receive either coronary angiography within 72 h and subsequent revascularisation, or medical therapy with coronary angiography only if they developed refractory ischaemia. The study demonstrated no difference between the two regimens with regards to mortality, MI or readmission. 41 However, there was moderate crossover between arms of the study, and a subsequent per protocol analysis of the data demonstrated significantly better outcomes (death and recurrent MI) with an invasive approach. 42 The benefits of invasive management in the elderly have been replicated in multiple trials, with improved short-term and long-term outcomes. 4, 43, 44 Despite these findings, patients aged >70 years are less likely to undergo coronary angiography than patients aged <70 years. 45 Factors explaining the preference for conservative management in the elderly may include higher risks of bleeding and concerns around quality of life, functional status and cognitive impairment. 46, 47 These concerns make the decision-making process in the elderly ACS population more nuanced, reflected in greater deviations from guideline-directed management. As emphasised in the cardiology society guidelines for the management of ACS, the focus of any treatment decision should always be patient-centred, with consideration of individual patient preferences, comorbidities, functional and cognitive status and life expectancy.
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POST-DISCHARGE CARE
After discharge, elderly patients remain at risk for recurrent coronary events. They are also at risk of medication non-compliance, with the strongest risk factors for nonadherence to prescribed medication being low education level, increased number of comorbidities and large pill burden. 48 As with all patients who have survived an ACS, referral to cardiac rehabilitation should be arranged, and careful clinical handover provided to their local medical practitioner. Patients aged >75 years are more likely than patients <50 years to visit their local medical practitioner post-ACS, and this is associated with increased participation in cardiac rehabilitation and receipt of medication scripts. 49 
CONCLUSION
There continues to be a notable lack of guideline recommendations specifically for elderly ACS patients. While large trials continue to exclude the elderly population who represent a large proportion of clinical practice, prescribers are left with uncertainty as to optimal management of elderly ACS patients. We suggest that pharmacotherapy in older patients should be individualised, taking into consideration the available evidence and the patient's unique profile of comorbidities, functional status, quality of life and treatment preferences.
